BiotechFQ
@biotechfq.bsky.social did:plc:wvb24cwtbzkq4tnyhwm322sw
#Biotech #GeneEditing #AI #IPSC #Neuroscience #Epigenetics #TPD
En Bluesky desde el
- Seguidores
- 8
- Siguiendo
- 13
- Posts
- 8
- Días en rankings
- 0
Resumen
BiotechFQ (@biotechfq.bsky.social) es un usuario de Bluesky que se unió el 17 noviembre 2024. Tiene 8 seguidores, sigue a 13 cuentas y ha publicado 8 posts.
Apariciones en rankings
Los mejores días en que los posts de esta cuenta entraron en la lista diaria de Debya.
Esta cuenta aún no ha aparecido en un ranking diario.
Posts que le gustaron recientemente
Me gusta públicos de la red Bluesky.
$ARVN Phase 3 VERITAC-2 trial showed that Vepdegestrant monotherapy significantly improves progression-free survival in ER+/HER2 breast cancer patients with ESR1 mutations, but not in the overall patient population. See More Biotech Updates👇 www.biopharmcatalyst.com/news/2025/2s...
Ver postRoche signs biggest-ever obesity drug deal with Danish Zealand Pharma; $5.3bn licensing agreement for next-generation treatment. www.ft.com/content/80c5...
Ver postZealand Pharma ( $ZEAL.CO) partners with Roche on its amylin analog in a deal worth up to $5.3B, plus 50% upside on profits, with $1.65Bn upfront! 👏 endpts.com/zealand-part...
Ver post$TSVT announced a merger agreement with $BMY to be acquired for $5.00 per share in an all-cash deal valued at $286 million, representing an 88% premium to its March 7, 2025 closing price. See More Pre-market Movers 👇 www.biopharmcatalyst.com/news/2025/2s... $ARVN $CUTR $SNOA $TNON $BVS $MYO $HCSC
Ver post$BTAI announced that it has achieved 33% enrollment in its 200-patient SERENITY At-Home trial, a pivotal Phase 3 study assessing the safety of BXCL501. See More Biotech Updates👇 www.biopharmcatalyst.com/news/2025/bi...
Ver post
Cuentas que bloquea
En Bluesky los bloqueos son registros públicos.
Esta cuenta no bloquea a nadie.